{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:25:04Z","timestamp":1793744704636,"version":"4.6.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF21OC0066562"],"award-info":[{"award-number":["NNF21OC0066562"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Det Frie Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["0129-00005B"],"award-info":[{"award-number":["0129-00005B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007505","name":"Kirsten og Freddy Johansens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007505","id-type":"DOI","asserted-by":"publisher"}]},{"name":"German Federal Ministry of Education and Research","award":["Fkz 01EK1507A-C"],"award-info":[{"award-number":["Fkz 01EK1507A-C"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["AB58\/10-2"],"award-info":[{"award-number":["AB58\/10-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chimeric antigen receptor (CAR) redirected T-cells has shown efficacy in the treatment of B-cell leukemia\/lymphoma, however, high numbers of relapses occur due to loss of targeted antigen or intrinsic failure of the CAR T-cells. In this situation modifications of the basic strategy are envisaged to reduce the risk of relapse, some of them are in early clinical exploration. These include simultaneous targeting of multiple antigens or combination of CAR T-cell therapy with other treatment modalities such as checkpoint inhibitors. The review evaluates and discusses these modified advanced therapies and pre-clinical approaches with respect to their potential to control leukemia and lymphoma in the long-term.<\/jats:p>","DOI":"10.1007\/s00262-022-03163-y","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T20:02:21Z","timestamp":1645646541000},"page":"2301-2311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials"],"prefix":"10.1007","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0997-8262","authenticated-orcid":false,"given":"Maria","family":"Ormh\u00f8j","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinrich","family":"Abken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sine R.","family":"Hadrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"key":"3163_CR1","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1089\/hum.2021.165","volume":"32","author":"H Abken","year":"2021","unstructured":"Abken H (2021) Building on synthetic immunology and T cell engineering: a brief journey through the history of CARs. Hum Gene Ther 32:1011","journal-title":"Hum Gene Ther"},{"issue":"5","key":"3163_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/2326-6066.CIR-14-0195","volume":"3","author":"I Liadi","year":"2015","unstructured":"Liadi I, Singh H, Romain G, Rey-Villamizar N, Merouane A, Adolacion JR et al (2015) Individual motile CD4(+) T cells can participate in efficient multikilling through conjugation to multiple tumor cells. Cancer Immunol Res 3(5):473\u2013482","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"3163_CR3","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.immuni.2016.02.023","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, RS OC, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr et al (2016) Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44(3):712","journal-title":"Immunity"},{"issue":"544","key":"3163_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aat6753","volume":"11","author":"AI Salter","year":"2018","unstructured":"Salter AI, Ivey RG, Kennedy JJ, Voillet V, Rajan A, Alderman EJ et al (2018) Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci Signal 11(544):eaat6753","journal-title":"Sci Signal"},{"issue":"9","key":"3163_CR5","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1016\/j.ymthe.2018.07.005","volume":"26","author":"V Golumba-Nagy","year":"2018","unstructured":"Golumba-Nagy V, Kuehle J, Hombach AA, Abken H (2018) CD28-zeta CAR T cells resist TGF-beta repression through IL-2 signaling, which can be mimicked by an engineered IL-7 autocrine loop. Mol Ther 26(9):2218\u20132230","journal-title":"Mol Ther"},{"issue":"17","key":"3163_CR6","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","volume":"71","author":"M Chmielewski","year":"2011","unstructured":"Chmielewski M, Kopecky C, Hombach AA, Abken H (2011) IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res 71(17):5697\u20135706","journal-title":"Cancer Res"},{"issue":"4","key":"3163_CR7","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","volume":"25","author":"MC O'Leary","year":"2019","unstructured":"O\u2019Leary MC, Lu X, Huang Y, Lin X, Mahmood I, Przepiorka D et al (2019) FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res 25(4):1142\u20131146","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3163_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S et al (2018) CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med 24(1):20\u201328","journal-title":"Nat Med"},{"issue":"17","key":"3163_CR9","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1200\/JCO.19.03279","volume":"38","author":"NN Shah","year":"2020","unstructured":"Shah NN, Highfill SL, Shalabi H, Yates B, Jin J, Wolters PL et al (2020) CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial. J Clin Oncol 38(17):1938\u20131950","journal-title":"J Clin Oncol"},{"issue":"1","key":"3163_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","volume":"13","author":"H Dai","year":"2020","unstructured":"Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D et al (2020) Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol 13(1):30","journal-title":"J Hematol Oncol"},{"key":"3163_CR11","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1182\/blood-2019-123424","volume":"134","author":"PJ Amrolia","year":"2019","unstructured":"Amrolia PJ, Wynn R, Hough RE, Vora A, Bonney D, Veys P et al (2019) Phase I study of AUTO3, a bicistronic chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and CD22, in pediatric patients with relapsed\/refractory B-cell acute lymphoblastic leukemia (r\/r B-ALL): amelia study. Blood 134:2620","journal-title":"Blood"},{"issue":"10","key":"3163_CR12","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1172\/JCI87366","volume":"126","author":"M Ruella","year":"2016","unstructured":"Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J et al (2016) Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest 126(10):3814\u20133826","journal-title":"J Clin Invest"},{"key":"3163_CR13","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1182\/blood-2018-99-118526","volume":"132","author":"S Tu","year":"2018","unstructured":"Tu S, Deng L, Huang R, Zhou X, Yang J, Zhou W et al (2018) A novel chimeric antigen receptor T cells therapy strategy that dual targeting CD19 and CD123 to treat relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Blood 132:4015","journal-title":"Blood"},{"issue":"1","key":"3163_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2174\/1566523218666181116093857","volume":"19","author":"S Nair","year":"2019","unstructured":"Nair S, Wang JB, Tsao ST, Liu Y, Zhu W, Slayton WB et al (2019) Functional improvement of chimeric antigen receptor through intrinsic interleukin-15Ralpha signaling. Curr Gene Ther 19(1):40\u201353","journal-title":"Curr Gene Ther"},{"issue":"11","key":"3163_CR15","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.3390\/ijms20112764","volume":"20","author":"DC Harrer","year":"2019","unstructured":"Harrer DC, Schuler G, Dorrie J, Schaft N (2019) CSPG4-specific CAR T cells for high-risk childhood B cell precursor leukemia. Int J Mol Sci 20(11):2764","journal-title":"Int J Mol Sci"},{"issue":"511","key":"3163_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw9414","volume":"11","author":"H Qin","year":"2019","unstructured":"Qin H, Dong Z, Wang X, Cheng WA, Wen F, Xue W et al (2019) CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. Sci Transl Med 11(511):eaaw9414","journal-title":"Sci Transl Med"},{"issue":"10","key":"3163_CR17","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s00262-020-02614-8","volume":"69","author":"Z Dong","year":"2020","unstructured":"Dong Z, Cheng WA, Smith DL, Huang B, Zhang T, Chang WC et al (2020) Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions. Cancer Immunol Immunother 69(10):2139\u20132145","journal-title":"Cancer Immunol Immunother"},{"issue":"95","key":"3163_CR18","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A et al (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95):95ra73","journal-title":"Sci Transl Med"},{"issue":"8","key":"3163_CR19","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365(8):725\u2013733","journal-title":"N Engl J Med"},{"issue":"19","key":"3163_CR20","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1182\/blood.2019002936","volume":"135","author":"J Gauthier","year":"2020","unstructured":"Gauthier J, Hirayama AV, Purushe J, Hay KA, Lymp J, Li DH et al (2020) Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood 135(19):1650\u20131660","journal-title":"Blood"},{"issue":"10","key":"3163_CR21","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","volume":"26","author":"NN Shah","year":"2020","unstructured":"Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA et al (2020) Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med 26(10):1569\u20131575","journal-title":"Nat Med"},{"issue":"7","key":"3163_CR22","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1172\/JCI86000","volume":"126","author":"CA Ramos","year":"2016","unstructured":"Ramos CA, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O et al (2016) Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains. J Clin Invest 126(7):2588\u20132596","journal-title":"J Clin Invest"},{"issue":"13","key":"3163_CR23","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1182\/blood-2016-01-692046","volume":"128","author":"E Faitschuk","year":"2016","unstructured":"Faitschuk E, Hombach AA, Frenzel LP, Wendtner CM, Abken H (2016) Chimeric antigen receptor T cells targeting Fc mu receptor selectively eliminate CLL cells while sparing healthy B cells. Blood 128(13):1711\u20131722","journal-title":"Blood"},{"issue":"8","key":"3163_CR24","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S et al (2021) Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 384(8):705\u2013716","journal-title":"N Engl J Med"},{"issue":"19","key":"3163_CR25","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","volume":"116","author":"J Xu","year":"2019","unstructured":"Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu YF et al (2019) Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma. Proc Natl Acad Sci USA 116(19):9543\u20139551","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"3163_CR26","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","volume":"131","author":"L Lee","year":"2018","unstructured":"Lee L, Draper B, Chaplin N, Philip B, Chin M, Galas-Filipowicz D et al (2018) An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma. Blood 131(7):746\u2013758","journal-title":"Blood"},{"key":"3163_CR27","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1182\/blood-2019-126689","volume":"132","author":"R Popat","year":"2019","unstructured":"Popat R, Zweegman S, Cavet J, Yong PK, Lee L, Faulkner J et al (2019) Phase 1 first-in-human study of AUTO2, the first chimeric antigen receptor (CAR) T cell targeting APRIL for patients with relapsed\/refractory multiple myeloma (RRMM). Blood 132:3112","journal-title":"Blood"},{"issue":"11","key":"3163_CR28","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","volume":"373","author":"AL Garfall","year":"2015","unstructured":"Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ et al (2015) Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med 373(11):1040\u20131047","journal-title":"N Engl J Med"},{"issue":"8","key":"3163_CR29","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120505","volume":"3","author":"AL Garfall","year":"2018","unstructured":"Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M et al (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3(8):e120505","journal-title":"JCI Insight"},{"issue":"8","key":"3163_CR30","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","volume":"25","author":"E Drent","year":"2017","unstructured":"Drent E, Themeli M, Poels R, de Jong-Korlaar R, Yuan H, de Bruijn J et al (2017) A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization. Mol Ther 25(8):1946\u20131958","journal-title":"Mol Ther"},{"issue":"5","key":"3163_CR31","doi-asserted-by":"publisher","first-page":"e0197349","DOI":"10.1371\/journal.pone.0197349","volume":"13","author":"E Drent","year":"2018","unstructured":"Drent E, Poels R, Mulders MJ, van de Donk N, Themeli M, Lokhorst HM et al (2018) Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design. PLoS ONE 13(5):e0197349","journal-title":"PLoS ONE"},{"key":"3163_CR32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","volume":"2","author":"B Guo","year":"2015","unstructured":"Guo B, Chen M, Han Q, Hui F, Dai H, Zhang W et al (2015) CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma. J Cell Immunother 2:28\u201335","journal-title":"J Cell Immunother"},{"issue":"2","key":"3163_CR33","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.ymthe.2020.10.008","volume":"29","author":"C Amatya","year":"2021","unstructured":"Amatya C, Pegues MA, Lam N, Vanasse D, Geldres C, Choi S et al (2021) Development of CAR T cells expressing a suicide gene plus a chimeric antigen receptor targeting signaling lymphocytic-activation molecule F7. Mol Ther 29(2):702\u2013717","journal-title":"Mol Ther"},{"issue":"485","key":"3163_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746","volume":"11","author":"EL Smith","year":"2019","unstructured":"Smith EL, Harrington K, Staehr M, Masakayan R, Jones J, Long TJ et al (2019) GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med 11(485):eaau7746","journal-title":"Sci Transl Med"},{"issue":"12","key":"3163_CR35","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/nm.4431","volume":"23","author":"N Hosen","year":"2017","unstructured":"Hosen N, Matsunaga Y, Hasegawa K, Matsuno H, Nakamura Y, Makita M et al (2017) The activated conformation of integrin beta7 is a novel multiple myeloma-specific target for CAR T cell therapy. Nat Med 23(12):1436\u20131443","journal-title":"Nat Med"},{"issue":"1","key":"3163_CR36","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","volume":"7","author":"SH Baumeister","year":"2019","unstructured":"Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK et al (2019) Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma. Cancer Immunol Res 7(1):100\u2013112","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"3163_CR37","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","volume":"11","author":"E Zah","year":"2020","unstructured":"Zah E, Nam E, Bhuvan V, Tran U, Ji BY, Gosliner SB et al (2020) Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat Commun 11(1):2283","journal-title":"Nat Commun"},{"issue":"10","key":"3163_CR38","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","volume":"6","author":"Z Yan","year":"2019","unstructured":"Yan Z, Cao J, Cheng H, Qiao J, Zhang H, Wang Y et al (2019) A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol 6(10):e521\u2013e529","journal-title":"Lancet Haematol"},{"issue":"14","key":"3163_CR39","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT et al (2020) KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 382(14):1331\u20131342","journal-title":"N Engl J Med"},{"issue":"5","key":"3163_CR40","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","volume":"23","author":"CM Wang","year":"2017","unstructured":"Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH et al (2017) Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: an open-label phase I trial. Clin Cancer Res 23(5):1156\u20131166","journal-title":"Clin Cancer Res"},{"issue":"14","key":"3163_CR41","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/blood-2018-04-842708","volume":"132","author":"I Scarfo","year":"2018","unstructured":"Scarfo I, Ormhoj M, Frigault MJ, Castano AP, Lorrey S, Bouffard AA et al (2018) Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood 132(14):1495\u20131506","journal-title":"Blood"},{"issue":"3","key":"3163_CR42","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11523-020-00729-7","volume":"15","author":"S Ding","year":"2020","unstructured":"Ding S, Mao X, Cao Y, Wang N, Xu H, Zhou J (2020) Targeting CD79b for chimeric antigen receptor T-cell therapy of B-cell lymphomas. Target Oncol 15(3):365\u2013375","journal-title":"Target Oncol"},{"issue":"23","key":"3163_CR43","doi-asserted-by":"publisher","first-page":"7046","DOI":"10.1158\/1078-0432.CCR-19-1337","volume":"25","author":"M Ormhoj","year":"2019","unstructured":"Ormhoj M, Scarfo I, Cabral ML, Bailey SR, Lorrey SJ, Bouffard AA et al (2019) Chimeric antigen receptor T cells targeting CD79b Show efficacy in lymphoma with or without cotargeting CD19. Clin Cancer Res 25(23):7046\u20137057","journal-title":"Clin Cancer Res"},{"issue":"12","key":"3163_CR44","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/nm.4444","volume":"23","author":"PM Maciocia","year":"2017","unstructured":"Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC et al (2017) Targeting the T cell receptor beta-chain constant region for immunotherapy of T cell malignancies. Nat Med 23(12):1416\u20131423","journal-title":"Nat Med"},{"issue":"23","key":"3163_CR45","doi-asserted-by":"publisher","first-page":"5925","DOI":"10.1182\/bloodadvances.2020003218","volume":"4","author":"TJ Voorhees","year":"2020","unstructured":"Voorhees TJ, Ghosh N, Grover N, Block J, Cheng C, Morrison K et al (2020) Long-term remission in multiply relapsed enteropathy-associated T-cell lymphoma following CD30 CAR T-cell therapy. Blood Adv 4(23):5925\u20135928","journal-title":"Blood Adv"},{"issue":"9","key":"3163_CR46","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","volume":"127","author":"JA Fraietta","year":"2016","unstructured":"Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM et al (2016) Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood 127(9):1117\u20131127","journal-title":"Blood"},{"issue":"22","key":"3163_CR47","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N et al (2018) T Cells genetically modified to express an Anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol 36(22):2267\u20132280","journal-title":"J Clin Oncol"},{"issue":"18","key":"3163_CR48","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D et al (2019) Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 380(18):1726\u20131737","journal-title":"N Engl J Med"},{"key":"3163_CR49","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/blood-2019-126660","volume":"134","author":"JG Berdeja","year":"2019","unstructured":"Berdeja JG, Alsina M, Shah ND, Siegel DS, Jagannath S, Madduri D et al (2019) Updated results from an ongoing phase 1 clinical study of bb21217 anti-Bcma CAR T. Blood 134:927","journal-title":"Blood"},{"key":"3163_CR50","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2020-142695","volume":"136","author":"CL Costello","year":"2020","unstructured":"Costello CL, Cohen AD, Patel KK, Ali SS, Berdeja JG, Shah N et al (2020) Phase 1\/2 study of the safety and response of P-BCMA-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM) (PRIME) with novel therapeutic strategies. Blood 136:29\u201330","journal-title":"Blood"},{"issue":"10","key":"3163_CR51","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/protein\/gzu016","volume":"27","author":"MD Diem","year":"2014","unstructured":"Diem MD, Hyun L, Yi F, Hippensteel R, Kuhar E, Lowenstein C et al (2014) Selection of high-affinity Centyrin FN3 domains from a simple library diversified at a combination of strand and loop positions. Protein Eng Des Sel 27(10):419\u2013429","journal-title":"Protein Eng Des Sel"},{"issue":"16","key":"3163_CR52","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1182\/blood.2021010858","volume":"138","author":"KP Micklethwaite","year":"2021","unstructured":"Micklethwaite KP, Gowrishankar K, Gloss BS, Li Z, Street JA, Moezzi L et al (2021) Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood 138(16):1391\u20131405","journal-title":"Blood"},{"issue":"16","key":"3163_CR53","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1182\/blood.2021010813","volume":"138","author":"DC Bishop","year":"2021","unstructured":"Bishop DC, Clancy LE, Simms R, Burgess J, Mathew G, Moezzi L et al (2021) Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells. Blood 138(16):1504\u20131509","journal-title":"Blood"},{"issue":"2","key":"3163_CR54","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11899-017-0373-2","volume":"12","author":"M Ormhoj","year":"2017","unstructured":"Ormhoj M, Bedoya F, Frigault MJ, Maus MV (2017) CARs in the lead against multiple myeloma. Curr Hematol Malig Rep 12(2):119\u2013125","journal-title":"Curr Hematol Malig Rep"},{"issue":"26","key":"3163_CR55","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","volume":"130","author":"T Gogishvili","year":"2017","unstructured":"Gogishvili T, Danhof S, Prommersberger S, Rydzek J, Schreder M, Brede C et al (2017) SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes. Blood 130(26):2838\u20132847","journal-title":"Blood"},{"issue":"5","key":"3163_CR56","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/bjh.12563","volume":"163","author":"R Hajek","year":"2013","unstructured":"Hajek R, Okubote SA, Svachova H (2013) Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. Br J Haematol 163(5):551\u2013564","journal-title":"Br J Haematol"},{"issue":"21","key":"3163_CR57","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1182\/bloodadvances.2019000703","volume":"3","author":"A Schmidts","year":"2019","unstructured":"Schmidts A, Ormhoj M, Choi BD, Taylor AO, Bouffard AA, Scarfo I et al (2019) Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv 3(21):3248\u20133260","journal-title":"Blood Adv"},{"issue":"19","key":"3163_CR58","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","volume":"134","author":"MJ Pont","year":"2019","unstructured":"Pont MJ, Hill T, Cole GO, Abbott JJ, Kelliher J, Salter AI et al (2019) Gamma-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood 134(19):1585\u20131597","journal-title":"Blood"},{"issue":"1","key":"3163_CR59","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","volume":"24","author":"X Wang","year":"2018","unstructured":"Wang X, Walter M, Urak R, Weng L, Huynh C, Lim L et al (2018) Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma. Clin Cancer Res 24(1):106\u2013119","journal-title":"Clin Cancer Res"},{"issue":"9","key":"3163_CR60","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1172\/JCI94306","volume":"127","author":"CA Ramos","year":"2017","unstructured":"Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z et al (2017) Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest 127(9):3462\u20133471","journal-title":"J Clin Invest"},{"issue":"8","key":"3163_CR61","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/mt.2016.82","volume":"24","author":"AA Hombach","year":"2016","unstructured":"Hombach AA, Gorgens A, Chmielewski M, Murke F, Kimpel J, Giebel B et al (2016) Superior therapeutic index in lymphoma therapy: CD30(+) CD34(+) hematopoietic stem cells resist a chimeric antigen receptor T-cell attack. Mol Ther 24(8):1423\u20131434","journal-title":"Mol Ther"},{"key":"3163_CR62","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1182\/blood-2018-99-119009","volume":"132","author":"F Chu","year":"2018","unstructured":"Chu F, Weng J, Kuang S, Cheng X, Cao J, Liu J et al (2018) Targeting CAR T resistance due to CD19 loss with CD79b-specific CAR T cells in B-cell malignancies. Blood 132:1662","journal-title":"Blood"},{"issue":"16_Supplement","key":"3163_CR63","doi-asserted-by":"publisher","first-page":"CT055","DOI":"10.1158\/1538-7445.AM2020-CT055","volume":"80","author":"CA Jacobson","year":"2020","unstructured":"Jacobson CA, Westin JR, Miklos DB, Herrera AF, Lee J, Seng J et al (2020) Abstract CT055: phase 1\/2 primary analysis of ZUMA-6: axicabtagene ciloleucel (Axi-Cel) in combination With atezolizumab (Atezo) for the treatment of patients (pts) with refractory diffuse large B cell lymphoma (DLBCL). Cancer Res 80(16_Supplement):CT055","journal-title":"Cancer Res"},{"issue":"4","key":"3163_CR64","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Condomines M, van der Stegen SJC, Perna F, Kloss CC, Gunset G et al (2015) Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28(4):415\u2013428","journal-title":"Cancer Cell"},{"issue":"4","key":"3163_CR65","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/mt.2015.4","volume":"23","author":"KJ Curran","year":"2015","unstructured":"Curran KJ, Seinstra BA, Nikhamin Y, Yeh R, Usachenko Y, van Leeuwen DG et al (2015) Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther 23(4):769\u2013778","journal-title":"Mol Ther"},{"key":"3163_CR66","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/hon.124_2629","volume":"37","author":"CL Batlevi","year":"2019","unstructured":"Batlevi CL, Palomba ML, Park J, Mead E, Santomasso B, Riviere I et al (2019) Phase I clinical trial of CD19-targeted 19\u201328Z\/4-1BBL \u201carmored\u201d CAR T cells in patients with relapsed or refractory NHL and CLL including richter transformation. Hematol Oncol 37:166","journal-title":"Hematol Oncol"},{"issue":"5","key":"3163_CR67","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S et al (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24(5):563\u2013571","journal-title":"Nat Med"},{"key":"3163_CR68","doi-asserted-by":"publisher","first-page":"673276","DOI":"10.3389\/fonc.2021.673276","volume":"11","author":"F Marofi","year":"2021","unstructured":"Marofi F, Al-Awad AS, Sulaiman Rahman H, Markov A, Abdelbasset WK, Ivanovna Enina Y et al (2021) CAR-NK cell: a new paradigm in tumor immunotherapy. Front Oncol 11:673276","journal-title":"Front Oncol"},{"key":"3163_CR69","doi-asserted-by":"publisher","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","volume":"59","author":"G Xie","year":"2020","unstructured":"Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J (2020) CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine 59:102975","journal-title":"EBioMedicine"},{"issue":"1","key":"3163_CR70","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","volume":"1","author":"MV Maus","year":"2013","unstructured":"Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X et al (2013) T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 1(1):26\u201331","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"3163_CR71","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1182\/blood-2010-07-294520","volume":"117","author":"CH Lamers","year":"2011","unstructured":"Lamers CH, Willemsen R, van Elzakker P, van Steenbergen-Langeveld S, Broertjes M, Oosterwijk-Wakka J et al (2011) Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117(1):72\u201382","journal-title":"Blood"},{"issue":"6","key":"3163_CR72","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","volume":"18","author":"DL Wagner","year":"2021","unstructured":"Wagner DL, Fritsche E, Pulsipher MA, Ahmed N, Hamieh M, Hegde M et al (2021) Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol 18(6):379\u2013393","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"3163_CR73","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","volume":"16","author":"MC Jensen","year":"2010","unstructured":"Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR et al (2010) Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transpl 16(9):1245\u20131256","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7709","key":"3163_CR74","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ et al (2018) Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558(7709):307\u2013312","journal-title":"Nature"},{"issue":"12","key":"3163_CR75","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.3390\/cancers13122941","volume":"13","author":"LRC Barros","year":"2021","unstructured":"Barros LRC, Paixao EA, Valli AMP, Naozuka GT, Fassoni AC, Almeida RC (2021) CARTmath-A mathematical model of CAR-T immunotherapy in preclinical studies of hematological cancers. Cancers (Basel) 13(12):2941","journal-title":"Cancers (Basel)"},{"issue":"7","key":"3163_CR76","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s00262-020-02516-9","volume":"69","author":"A Globerson Levin","year":"2020","unstructured":"Globerson Levin A, Kronik N, Shiloach T, Waks T, Eshhar Z, Vainstein V (2020) Less is more: reducing the number of administered chimeric antigen receptor T cells in a mouse model using a mathematically guided approach. Cancer Immunol Immunother 69(7):1165\u20131175","journal-title":"Cancer Immunol Immunother"},{"key":"3163_CR77","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","volume":"16","author":"S Tyagarajan","year":"2020","unstructured":"Tyagarajan S, Spencer T, Smith J (2020) Optimizing CAR-T Cell manufacturing processes during pivotal clinical trials. Mol Ther Methods Clin Dev 16:136\u2013144","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"3163_CR78","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L (2020) \u201cOff-the-shelf\u201d allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov 19(3):185\u2013199","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"3163_CR79","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R et al (2020) Use of CAR-transduced natural killer cells in CD19-Positive lymphoid tumors. N Engl J Med 382(6):545\u2013553","journal-title":"N Engl J Med"},{"issue":"11","key":"3163_CR80","doi-asserted-by":"publisher","first-page":"e9158","DOI":"10.15252\/emmm.201809158","volume":"10","author":"A Pfeiffer","year":"2018","unstructured":"Pfeiffer A, Thalheimer FB, Hartmann S, Frank AM, Bender RR, Danisch S et al (2018) In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome. EMBO Mol Med 10(11):e9158","journal-title":"EMBO Mol Med"},{"issue":"8","key":"3163_CR81","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","volume":"28","author":"S Agarwal","year":"2020","unstructured":"Agarwal S, Hanauer JDS, Frank AM, Riechert V, Thalheimer FB, Buchholz CJ (2020) In vivo generation of CAR T cells selectively in human CD4(+) lymphocytes. Mol Ther 28(8):1783\u20131794","journal-title":"Mol Ther"},{"issue":"1","key":"3163_CR82","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","volume":"11","author":"NN Parayath","year":"2020","unstructured":"Parayath NN, Stephan SB, Koehne AL, Nelson PS, Stephan MT (2020) In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat Commun 11(1):6080","journal-title":"Nat Commun"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03163-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-022-03163-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03163-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T14:03:39Z","timestamp":1666620219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-022-03163-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,23]]},"references-count":82,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["3163"],"URL":"https:\/\/doi.org\/10.1007\/s00262-022-03163-y","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,23]]},"assertion":[{"value":"26 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}